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Abstract
Background. Tinidazole (TNZ) is an anti-parasite drug used in the treatment of a variety of amebic and 
parasitic infections. It has low solubility in aqueous media and is categorized under Class II of the Biophar-
maceutical Classification System.
Objectives. The aim of this research was to study the potential for enhancing the solubility of TNZ using 
carboxylic acid co-crystals.
Material and methods. The solubility of TNZ was determined individually using 6 carboxylic acids for 
forming co-crystals at a 1:1 stoichiometric ratio. Three carboxylic acids – namely tartaric acid (TA), oxalic 
acid (OA) and glutaric acid (GA) – resulted in the formation of co-crystals with enhanced solubility. An equ-
ilibrium solubility study of TNZ co-crystals at 1:1.5 and 1:2 stoichiometric ratios was also carried out. The co-
-crystals which developed were evaluated using X-ray powder diffraction (XRD) and differential scanning 
calorimetry (DSC) to study the drug–co-crystal former interactions.
Results. The solubility of TNZ in distilled water was found to be 0.014 mg/mL. The highest enhancement 
ratio was obtained with TNZ and TA at a ratio of 1:1. Differential scanning calorimetry thermograms sugge-
sted that the drug and carboxylic acids had undergone interactions such as hydrogen bonding. The XRD and 
DSC results confirmed the formation of co-crystals.
Conclusions. It was concluded that the results of enhanced solubility of TNZ using co-crystals is a clear in-
dication of the potential for co-crystals to be used in the future for other poorly water-soluble drugs, consi-
dering that co-crystals are a safe and cost-effective approach.
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Introduction 
Pharmaceutical co-crystals are multi-component crys-
tals based on hydrogen bonds without the transfer of 
hydrogen ions to form salts.1 Co-crystal formation has 
recently gained attention in pharmaceutical applications. 
The ability to tailor the physicochemical properties of 
a substance via complexation is highly desirable in terms 
of dissolution rate, bioavailability, stability, and process-
ing.2–5 Co-crystals can also enhance the flowability, com-
pressibility and hygroscopicity of drugs.6 A co-crystal may 
be defined as a material which contains 2 or more discrete 
molecular entities in its crystal lattice.7 In pharmaceuti-
cal terms, a co-crystal is a molecular complex of an active 
pharmaceutical ingredient and a second molecule, known 
as a  co-crystal former, which typically requires comple-
mentary hydrogen bonding between the 2 components.8 
Co-crystallization may influence the pharmacokinetics 
of therapeutically active compounds, which may in turn 
influence their biopharmaceutical and bioavailability 
properties, including absorption.9–11 The components in 
a co-crystal exist in a definite stoichiometric ratio, and are 
assembled via non-covalent interactions such as hydro-
gen bonds, ionic bonds, π–π, or van der Waals interac-
tions rather than by ion pairing.12
Tinidazole [1-(2-ethylsulfonylethyl)-2-methyl-5-nitro-
imidazole] (TNZ) (Fig. 1) is an anti-parasite drug used 
against protozoan infections. It may also be used as part 
of a combination therapy for Helicobacter pylori eradica-
tion. It has low solubility in aqueous media and is catego-
rized as Class II in the Biopharmaceutical Classification 
System.13 This property makes the drug a suitable candi-
date for research investigating new salts with improved 
solubility.
The aim of this work was to explore the possibility of 
TNZ co-crystal formation with various carboxylic acids, 
with an emphasis on determining whether it can form co-
crystals with multiple stoichiometries. A  method based 
on solvent evaporation was used to determine the possi-
bility of forming co-crystals from the 2 components.
The spherical crystallization technique is a  novel ag-
glomeration method for liquid systems which was de-
veloped by Kawashima in the 1980s.1 In this system, 
agglomeration and spheroidization can be carried out 
simultaneously during the crystallization process of 
a  substance with a bridging liquid by means of stirring. 
In the beginning, the spherical crystallization technique 
was mainly used in direct tableting technology because 
crystallization and agglomeration could be carried out si-
multaneously in a single step. The resultant agglomerates 
exhibited dramatically improved flowability, packability 
and compressibility.2,3 Later on, functional drug devices 
such as microspheres,4 microcapsules,5 microballoons,6 
and biodegradable nanospheres7 were developed using 
the emulsion-solvent-diffusion method, one of the spher-
ical crystallization techniques involving the introduction 
of a functional polymer into the system. 
Material and methods 
Material 
The TNZ was received as a gift sample by Aarti Drugs 
Ltd., Mumbai, India. Tartaric acid (TA), oxalic acid (OA), 
glutaric acid (GA), citric acid, salicylic acid, malonic acid, 
magnesium stearate, talc, and lactose monohydrate were 
purchased from Research-Lab Fine Chem Industries, 
Mumbai, India. Sodium starch glycolate and microcrys-
talline cellulose were purchased from BASF India Ltd., 
Mumbai, India. Methanol was purchased from Thomas 
Baker Chemicals, Mumbai, India. All other reagents were 
of analytical grade.
Methods 
Determination of solubility 
The saturation solubility of TNZ was determined in dis-
tilled water. In brief, 100 mg of TNZ was added to the dis-
tilled water and kept in an incubator shaker (100 rpm) for 
24 h at 37°C. After 24 h, the solution was centrifuged at 
2000 rpm for 15 min and filtered through Whatman grade 
41 filter paper. The supernatant was diluted with distilled 
water and its absorbance was measured at 318 nm using 
a UV spectrophotometer (model V-630; Shimadzu Cor-
poration, Kyoto, Japan). The saturation solubility was 
then calculated.
Preliminary trials for the preparation of TNZ co-crystals 
Based on the literature,14–18 6 carboxylic acids were ini-
tially selected for producing co-crystals of TNZ at a 1:1 
stoichiometric ratio. In brief, a precisely weighed amount 
of TNZ and individual carboxylic acids (TA, OA, GA, ma-
lonic acid, salicylic acid, and citric acid) at a 1:1 stoichio-
metric ratio were dissolved in methanol and sonicated for 
10 min in order to completely mix the ingredients. The re-
sulting solution was poured onto a Petri plate and stored 
Fig. 1. Chemical structure of TNZ
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to allow the solvent to completely evaporate at room tem-
perature (25°C). Co-crystals of TNZ formed with 3 of the 
carboxylic acids (TA, OA and GA). No co-crystals were 
obtained from malonic acid, salicylic acid or citric acid. 
Based on these results, TA, OA and GA were selected for 
further study and were used to produce TNZ co-crystals 
at 1:1.5 and 1:2 stoichiometric ratios (Table 1).
Equilibrium solubility study of TNZ co-crystals  
(1:1, 1:1.5, and 1:2 stoichiometric ratios) 
The solubility of TNZ in water from co-crystals formed 
with the 3 carboxylic acids remaining after screening 
(TA, OA and GA) was determined at room temperature 
using an incubator shaker (OS-02; Chromus Biotech, 
Bengaluru, India). Excess amounts of the TNZ co-crys-
tals with the individual carboxylic acids at different ra-
tios (Table 2) were added to 5 mL of distilled water and 
were shaken until a saturated solution was formed. The 
vials were shaken on a mechanical shaker for 24 h. The 
solution was then centrifuged at 2000 rpm for 10 min 
in an ultra-centrifuge and were filtered through What-
man grade 41 filter paper. Aliquots were suitably diluted 
with distilled water and methanol (1:1) and analyzed us-
ing a  UV spectrophotometer (model V-630; Shimadzu 
Corporation) at 318 nm.
Characterization of TNZ co-crystals 
Differential scanning calorimetry (DSC) 
To investigate the effect of temperature, thermograms 
of TNZ, TA, OA and GA, as well as of co-crystals of TNZ 
and the 3 carboxylic acids were recorded using a differen-
tial scanning calorimeter (DSC 4000 System; Perkin El-
mer, Waltham, USA). An empty aluminum pan was used 
as a  reference. The DSC measurements were taken at 
a heating rate of 10°C/min from 30°C to 300°C.19,20
X-ray powder diffraction analysis 
The physical state of pure TNZ and TNZ in co-crystals 
was examined using an X-ray diffraction analyzer (Phil-
ips 1710 powder X-ray diffractometer; Koninklijke Phil-
ips N.V., Amsterdam, the Netherlands). The X-ray dif-
fraction patterns were recorded using Cu Kα radiations 
(θ = 1.54059 Å), a current of 30 mA, and a voltage of 40 kV. 
The samples were analyzed over a 2θ range of 10–80.21–23
In vitro dissolution study 
The drug dissolution rates from different co-crystals 
were determined and compared to that of pure TNZ. The 
dissolution study was performed using a  United States 
Pharmacopeia (USP) type-II apparatus (model TDT-08L; 
Electrolab India, Mumbai, India). The dissolution medi-
um (900 mL of distilled water) was maintained at a tem-
perature of 37 ±0.5°C in the dissolution vessel. The co-
crystal equivalent of 300 mg of TNZ was placed into the 
dissolution vessel and the paddle was rotated at 50 rpm. 
Aliquots were withdrawn at 15 min intervals for 90 min. 
Those samples were filtered and analyzed using a  UV 
spectrophotometer (model V-630; Shimadzu Corpora-
tion) at 318 nm. The dissolution study was conducted in 
triplicate.19,20
Table 2. Formulation of TNZ tablets prepared by the direct-compression 
method (formulation T1)
Ingredients Quantity  [mg]
Co-crystal equivalent of 300 mg of tinidazole  
with tartaric acid (1:1)
482
Microcrystalline cellulose 60




Table 1. Results of solubility studies for TNZ–carboxylic acid co-crystals
Drug Carboxylic acid Quantity of drug  [mg]







TNZ tartaric acid 200 121.39 0.1540 ±0.002 11.00
TNZ oxalic acid 200 72.81 0.0700 ±0.001 5.00
TNZ glutaric acid 200 106.85 0.0784 ±0.001 5.60
1:1.5 stoichiometric ratio
TNZ tartaric acid 200 182.08 0.0995 ±0.002 7.10
TNZ oxalic acid 200 109.22 0.1445 ±0.003 10.32
TNZ glutaric acid 200 160.28 0.1183 ±0.002 8.45
1:2 stoichiometric ratio
TNZ tartaric acid 200 242.78 0.0995 ±0.001 1.12
TNZ oxalic acid 200 145.62 0.1445 ±0.002 3.41
TNZ glutaric acid 200 213.70 0.0160 ±0.001 1.18
* Data is presented as mean ± standard deviation (SD) (n = 3).
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Production of TNZ tablets  
by the direct-compression method 
Tablets of co-crystal equivalents of 300 mg of TNZ and 
TA (1:1) were prepared using the direct-compression 
method according to the formula given in Table 2. All of 
the ingredients were passed separately through a 60-mesh 
sieve. Co-crystals and microcrystalline cellulose were 
mixed by adding small amounts of each several times 
and blending them to obtain a uniform mixture and kept 
aside. The ingredients were then weighed and mixed in 
geometrical order and the tablets were compressed with 
a  Rimek Compression Machine using the 8-millimeter 
flat round punch. The resulting tablets were evaluated 
and the pre-compression and post-compression param-
eters were compared.
In vitro drug release study 
The in vitro drug release from the resulting tablets was 
studied using a USP type-II apparatus (USP XXIII Disso-
lution Test Apparatus; Electrolab India, Mumbai, India) 
at 100 rpm using 900 mL of distilled water as a  release 
medium. The temperature of the medium was maintained 
at 37 ±0.5°C. Aliquots were withdrawn at 30-minute in-
tervals for 180 min, then filtered and analyzed at 318 nm 
using a UV spectrophotometer (model V-630; Shimadzu 
Corporation). The drug concentration was determined 
from the standard calibration curve. The release profile 
of a commercially available TNZ tablet (300 mg of TNZ – 
Tiniba 300 tablet; Zydus Cadila, Ahmadabad, India) was 
compared with that of the tablets produced.
Results and discussion 
Some of the acids (TA, OA and GA) provided satisfac-
tory results in terms of safety for acceptance in therapy 
(Fig. 2). Hydrogen bonds occur between the nitrogen and 
sulfonyl oxygen of TNZ and the hydrogen of the hydroxyl 
group of TA. When it comes to OA and GA, the formation 
of hydrogen bonds between these atoms may not be favor-
able. The 2 carbon atoms separating the carboxyl groups 
(-COOH) from the hydrogen-bond donor hydroxyl groups 
in TA may be optimally suited to form such hydrogen 
bonds, whereas the 3 carbon atoms separating the carboxyl 
groups (-COOH) in GA – or 0 carbon atoms in the case of 
Fig. 2. The probable hydrogen bond formation between TNZ and tartaric 
acid (A), TNZ and oxalic acid (B), and TNZ and glutaric acid (C)
OA – may be less favorable than TA. The stronger ability of 
TA to form hydrogen bonds with TNZ may be responsible 
for the enhanced solubility of these co-crystals. 
Equilibrium solubility studies  
of the co-crystals 
The solubility of TNZ in distilled water was found to be 
0.014 mg/mL. Co-crystals of TNZ and tartaric acid dem-
onstrated maximum solubility at a stoichiometric ratio of 
1:1, while OA and GA co-crystals performed best at a ra-
tio of 1:1.5. The solubility enhancement ratios of the above 
combinations were 11.00 (TNZ:TA, 1:1), 10.32 (TNZ:OA, 
1:1.5), and 8.45 (TNZ:GA, 1:1.5), respectively (Table 1).
Differential scanning calorimetry analysis 
As the physical state of a drug influences its release kinet-
ics, differential scanning calorimetry (DSC) was conducted 
for the pure drug, for carboxylic acids and for the co-crys-
tals in order to determine the physical state of drug – i.e., 
amorphous or crystalline – before and after the production 
of co-crystals. The results of the DSC study are present-
ed in Fig. 3. The DSC spectrum of TNZ showed a sharp 
endothermic peak at 128°C, indicating its melting point 
(126–129°C). In the DSC thermogram of the co-crystals 
with enhanced solubility (TNZ:TA, 1:1, TNZ:OA, 1:1.5 and 
TNZ:GA, 1:1.5), the endothermic peaks of both the drug 
and the carboxylic acids (TA, OA and GA) were visible, but 
not very intense and slightly shifted from their original po-
sitions, indicating that the TNZ and the carboxylic acids 
had undergone interactions such as hydrogen bonding.
X-ray powder diffraction analysis 
X-ray diffraction was used to evaluate the physical state 
of TNZ and the drug within the co-crystals produced. The 
X-ray diffractograms of TNZ, the carboxylic acids and the 
co-crystals are presented in Fig. 4. Tinidazole displayed 
characteristic, intense peaks at 2θ of 10.62, 15.24, 17.84, 
18.18, 18.84, 21.23, 22.42, 23.87, 27.20, 27.63, 28.28, 29.57, 
31.28, 33.15, 35.26, 36.26, 37.26, 38.26, 31.21, 34.24, and 
39.46, indicating its crystalline nature.
Fig. 3. Differential scanning calorimetry analysis (DSC) of TNZ and co-crystals
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In the co-crystals prepared with TA, peaks of a reduced 
intensity were visible at 2θ of 11.39, 13.92, 15.84, 17.93, 
18.17, 19.42, 20.34, 21.14, 23.42, 32.34, 33.17, and 37.52, 
indicating that the drug is partly dissolved within the 
formed matrix and partly in an amorphous form distrib-
uted throughout the system.
The co-crystals with GA showed peaks at 2θ of 10.62, 
13.94, 17.24, 18.44, 19.14, 22.22, 24.24, 26.42, 25.13, 29.31, 
37.41, 41.16, and 49.46, while the co-crystals with OA 
demonstrated peaks at 2θ of 10.12, 11.95, 12.87, 14.24, 
16.14, 17.24, 18.24, 19.57, 20.11, 21.22, 23.24, 29.42, 30.23, 
31.37, 32.21, 37.86, and 49.34. Overall, the decrease in the 
number and intensity of peaks indicates that the drug is 
partly dissolved within the formed matrix and partly in 
a crystalline form distributed throughout the system; this 
confirms the formation and existence of co-crystals.
Dissolution profile of TNZ and TNZ  
co-crystals at different stoichiometric ratios 
The dissolution profiles of TNZ and co-crystals of TNZ 
with different carboxylic acids and at different stoichiomet-
ric ratios are presented in Fig. 5–7. From the equilibrium 
solubility studies and dissolution studies, it was determined 
that a 1:1 stoichiometric ratio is best for TNZ + TA co-crys-
tals. A 1:1.5 stoichiometric ratio was found to be best for 
TNZ + OA and TNZ + GA co-crystals. The analysis indi-
cates that TNZ + TA (1:1 stoichiometric ratio) performed 
the best of all the ratios, and was therefore selected for the 
production of tablets.
Evaluation of tablets 
Pre-compression parameters 
The small differences in the values of bulk density and 
tapped density illustrate the free-flowing nature of pow-
der blend. Hausner’s ratio was found to be 1.132, which 
indicates that the powder blend is free-flowing (Table 3). 
The value of compressibility index (15–16) and the angle 
of repose (30–31°) indicate good flowability, so the power 
blend can be used to directly manufacture directly com-
pressed tablets. 
Fig. 4. X-ray powrder diffraction (XRPD) spectra of (a) TNZ, (b) tartaric acid, 
(c) TNZ + tartaric acid (1:1), (d) glutaric acid, (e) TNZ + glutaric acid (1:1.5), 
(f ) oxalic acid, and (g) TNZ + oxalic acid (1:1:1.5)
Fig. 5. Dissolution profile of TNZ and TNZ co-crystals (1:1 ratio) in distilled 
water at 37°C ±0.5°C (data presented as mean ±SD, n = 3)
Fig. 6. Dissolution profile of TNZ and TNZ co-crystals (1:1.5 ratio) in distilled 
water at 37°C ±0.5°C (data presented as mean ±SD, n = 3)
Fig. 7. Dissolution profile of TNZ and co-crystals of TNZ (1:2 ratio) in 
distilled water at 37°C ±0.5°C (data presented as mean ±SD, n = 3)
Table 3. Results of pre-compression powder blend (formulation T1);  













of repose  
[°]
0.845 ±0.04 0.926 ±0.08 1.132 ±0.06 16.30 ±1.26 31.00 ±1.45
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Post-compression parameters 
The post-compression parameters of the tablets con-
taining TNZ–carboxylic acid co-crystals (formula-
tion T1) are as follows: the hardness of the tablets was 2.0 
±0.14  kg/cm2, their friability was 0.61 ±0.01%, the drug 
content was 97 ±0.82%, and the disintegration time was 
120 ±5 s (Table 4). All of the post-compression param-
eters were within the acceptable ranges.
In vitro release studies 
Figure 8 presents a  graph comparing the percentage 
of cumulative TNZ release over time for the tablets pro-
duced in this study vs a commercially available formula-
tion. The results indicate that after 2 h, the cumulative 
percentage release of formulation T1 was greater (74.23%) 
than that of the tablets available on the market (48.42%).
Conclusions 
Our study has clearly revealed that the application of 
carboxylic acid co-crystals is an effective and safe ap-
proach to increasing the dissolution rate of poorly water-
soluble drugs. We have demonstrated the utility of car-
boxylic acid co-crystals using a practically insoluble drug, 
TNZ, which is a clear indication of their potential applica-
tion in various other poorly water-soluble drugs.
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Drug content  
[%]
In vitro  
disintegration time 
[s]
2.00 ±0.14 0.61 ±0.01 97.00 ±0.82 120 ±5
